Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Beyondspring Inc (NQ: BYSI )

9.440 USD +0.070 (+0.75%)
Official Closing Price Updated: 7:12 PM EDT, Apr 21, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Beyondspring Inc

< Previous 1 2 3 4 5 Next >
BeyondSpring Announces Submission of New Drug Application to U.S. FDA and China NMPA for Plinabulin and G-CSF Combination for the Prevention of Chemotherapy-Induced Neutropenia (CIN)
From GlobeNewswire News Releases
BeyondSpring Hosting Key Opinion Leader Webinar on Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia
From GlobeNewswire News Releases
BeyondSpring to Present at the J.P. Morgan Healthcare Conference on January 14, 2021
From GlobeNewswire News Releases
BeyondSpring Announces the Appointment of Dr. Jeffrey Vacirca to its Board of Directors
From GlobeNewswire News Releases
BeyondSpring Announces New Positive PROTECTIVE-2 Phase 3 Registrational Trial Results at the 2020 San Antonio Breast Cancer Symposium
From GlobeNewswire News Releases
BeyondSpring to Present at Two Upcoming Scientific Conferences in December
From GlobeNewswire News Releases
BeyondSpring to Participate in Upcoming Evercore ISI 2020 Conference
From GlobeNewswire News Releases
BeyondSpring Announces Pricing of Ordinary Shares
From GlobeNewswire News Releases
BeyondSpring Announces Proposed Public Offering of Ordinary Shares
From GlobeNewswire News Releases
BeyondSpring Announces Third Quarter 2020 Financial Results and Provides Business Updates
From GlobeNewswire News Releases
BeyondSpring Announces Positive Topline Results from its PROTECTIVE-2 Phase 3 Registrational Trial of Plinabulin in Combination with Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia
From GlobeNewswire News Releases
BeyondSpring to Present Corporate Overview at Jefferies London Healthcare Conference
From GlobeNewswire News Releases
BeyondSpring Subsidiary, Seed Therapeutics, Announces Research Collaboration and License Agreement with Lilly
From GlobeNewswire News Releases
Seed Therapeutics Launches Protein Degradation Research Platform and Appoints Edward Dongheng Liu as Chief Financial Officer
“Molecular Glue” Protein Degradation Serves as Alternative Approach for Difficult-to-Treat Diseases 
From GlobeNewswire News Releases
BeyondSpring Forms Partnership Advisory Committee Comprised of Industry Veterans
Former Forty Seven and Roche Senior Executives to Support Partnering Efforts 
From GlobeNewswire News Releases
JAMA Oncology Highlights Plinabulin's Efficacy in Preventing Chemotherapy-Induced Neutropenia as a Monotherapy
From GlobeNewswire News Releases
New Data Highlights BeyondSpring’s Plinabulin as a Highly Effective Agent for Preventing Chemotherapy-Induced Neutropenia, with Potential to Reduce Clinical Resources for COVID-19
Poster Presentation at ESMO Congress 2020 Demonstrates Plinabulin’s Early Onset Protection, with a CIN Effect Comparable to Pegfilgrastim, Plus Improved Platelet Counts and Reduced Bone Pain 
From GlobeNewswire News Releases
BeyondSpring Appoints Elizabeth Czerepak as Chief Financial Officer
New Subsidiary Focused on Targeted Protein Degradation, Seed Therapeutics, Appoints Edward Liu as CFO 
From GlobeNewswire News Releases
BeyondSpring to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020
From GlobeNewswire News Releases
BeyondSpring Receives Breakthrough Therapy Designations from Both U.S. FDA and China NMPA for Plinabulin in Chemotherapy-Induced Neutropenia Indication
From GlobeNewswire News Releases
BeyondSpring Provides Second-Quarter 2020 Financial Results and Business Updates
From GlobeNewswire News Releases
BeyondSpring to Host Second-Quarter 2020 Financial Results and Operational Update Conference Call on September 3rd, 2020
From GlobeNewswire News Releases
BeyondSpring Appoints Forty Seven, Inc., Co-Founder and Stanford Hematology Veteran, Dr. Ravindra Majeti, to Board of Directors
Gilead Acquired Forty Seven in March 2020 for $4.9 Billion 
From GlobeNewswire News Releases
BeyondSpring Initiates Expanded Access Program with Plinabulin for Patients Suffering from CIN in the U.S.
From GlobeNewswire News Releases
New Stem Cell-Based Application for BeyondSpring’s Plinabulin Presented at ISSCR Annual Meeting
Data Presented Shows Plinabulin Mobilizes Bone Marrow CD34+ Progenitor Cells through a Mechanism of Action Independent from G-CSFs and CXCR4 
From GlobeNewswire News Releases
New Preclinical Data Demonstrates Immune-Enhancing Effects of Triple I/O Combination Therapy with BeyondSpring’s Plinabulin
From GlobeNewswire News Releases
BeyondSpring Announces Pricing of Ordinary Shares
From GlobeNewswire News Releases
BeyondSpring Announces Proposed Public Offering of Ordinary Shares
From GlobeNewswire News Releases
BeyondSpring Announces Positive Topline Interim Results from PROTECTIVE-2 (Study 106) Phase 3 Trial Evaluating Superiority of Plinabulin in Combination with Neulasta for Chemotherapy-Induced Neutropen
From GlobeNewswire News Releases
BeyondSpring Reports First-Quarter 2020 Financial Results and Operational Update
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.